Acute Urinary Retention from BPH: When Alpha Blocker and Trial Without Catheter Have Failed

In patients presenting with acute urinary retention (AUR) related to benign prostatic hyperplasia, an alpha blocker followed by a trial without catheter (TWOC) is the standard initial step. When that trial does not restore successful voiding and retention persists, a structured next-line approach is indicated.

Clinical Scenario

Acute urinary retention related to benign prostatic hyperplasia, in a patient who has undergone an alpha blocker-facilitated voiding trial without achieving successful voiding or resolution of retention.

Previous Line: Goals Not Achieved

An alpha blocker (alfuzosin or tamsulosin) was prescribed prior to a trial without catheter. The two required goals — successful voiding after the TWOC and resolution of urinary retention — were not met, indicating the need to escalate management.

Next-Line Approach (partial)

Surgical therapy is the recommended next step, with the operative approach determined by prostate size, anatomy, and clinical context — the complete protocol specifies the available options.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1097/JU.0000000000003698

Physicians should prescribe an oral alpha blocker prior to a voiding trial to treat patients with AUR related to BPH.

Surgery is recommended for patients who have renal insufficiency secondary to BPH, refractory urinary retention secondary to BPH, recurrent urinary tract infections (UTIs), recurrent bladder stones or gross hematuria due to BPH, and/or with LUTS/BPH refractory to or unwilling to use other therapies.

TURP should be offered as a treatment option for patients with LUTS/BPH.

View source ↗